Each year, the non-profit scientific and medical innovators invited to submit proposals for the opportunity to gain recognition and approval of essential MFIA, support for their ideas and secure funding, and gain introductions to key professional contacts and business for their ideas to the next level.‘I’m really honored that our work is recognized by the same organization that has introduced my mentor and friend, Sir James Black, with a Lifetime Achievement Award,’ Bond said, referring to the late British physician, known as the ‘Father of the beta -blockers. ‘
After years of being rejected by scientific journals and funded by national research agencies, the tide began to turn over the past two years, with the work of James Bond and being published in journals such as Proceedings of the National Academy of Sciences and The Lancet, and the assignment of a U.S. patent and has received nearly $ 1 million in research funding from the National Institutes of Health.
‘I still do not think of honors, such as the Medical Futures praised as a’ claim ‘in itself, because I always said I could be wrong,’ said Bond. ‘However, I have argued that investigations must be made so that we can be sure that we do not make the same mistake as we did with CHF.’
The success of the inverse agonist beta-blockers on the market could lead to a better quality of life for millions of patients with a variety of respiratory diseases including asthma, pulmonary disease and chronic.
At the University of Houston , professor of pharmacy for ten years in question the dogma of conventional medical treatment of honor earned him a prestigious international medical as an innovator.
Previous research on the use of beta-agonists, inverse transformed the medical community of the drug to be considered among the drugs may be administered as failure patients to what is now the standard of care for the disease.
At the University of Colorado at Boulder study shows that some types of transplants in the leg muscles of mice prevented the loss of muscle function and mass that normally occurs with aging, a finding with potential uses in treating humans with chronic , degenerative muscle diseases.
Bond for decades, and his past, UH, Baylor College of Medicine and MD Anderson Cancer Center have studied the use of employees, after a controversial class of compounds called beta-blockers in the treatment of benign inverse agonist, on chronic asthma. Their research has shown that if this type of drug causes an initial short-term, negative effects of increased airway narrowing, the effect seems to be reversed with long-term use.
Pharmacologist and two-time former UH, Richard A. Bond is the only researcher in the United States to be recognized at the Medical Futures Innovation Awards 2011 ceremony in London on June 6 Strive to bring innovative ideas for the commercial market and improve patient care, gives James Bond a commendation MFIA for his work on the use of drugs for the treatment of asthma and other respiratory diseases.